AP-04 is the first-in-class DNA base editor designed to inhibit cancer and metastasis. Antapodia Therapeutics leverages cutting-edge gene-editing technologies to disable the splicing of the mRNA encoding the invadopodial regulator MIR-01, achieving a permanent inactivation of its expression in cancer cells. The delivery of AP-04 to primary and metastatic cancer cells using next-generation LNPs provides an unprecedented “one-time” solution to treating cancer and preventing metastasis.


Designed by Justin V. Tsai in 2021

Copyright © Antapodia Therapeutics, Inc., WA, USA. All Rights Reserved.